HUMACYTE INC. - COMMO

Humacyte to Provide Human Acellular Vessels™ (HAVs™) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries

09 May 2022 07:00:02 By Nasdaq GlobeNewswire

Humacyte to Present First Quarter 2022 Financial Results and Provide Recent Corporate Update on May 13, 2022

06 May 2022 07:00:00 By Nasdaq GlobeNewswire

Humacyte Expands Leadership Team with Appointment of Shamik Parikh, M.D., as Chief Medical Officer

05 Apr 2022 07:00:03 By Nasdaq GlobeNewswire

Humacyte Announces Date of Annual Shareholder Meeting

04 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Humacyte Reports Fourth Quarter and Year End 2021 Financial Results and Provides Business Update

29 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

Humacyte to Present Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022

21 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Present at Upcoming Investor Conferences in March

01 Mar 2022 07:00:04 By Nasdaq GlobeNewswire

Humacyte Announces Publication of Positive Long-Term Follow-Up Data from Phase 2 Trial of HAV™ for Hemodialysis

28 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Humacyte to Participate in Fireside Chat at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

09 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Humacyte Announces Clinical Case Series Demonstrating Potential of Human Acellular Vessel™ (HAV™) to Expand Opportunities for Limb Salvage in Multiple Complex Vascular Reconstruction Scenarios

31 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Humacyte Announces Preclinical Results of Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting

28 Jan 2022 08:15:00 By Nasdaq GlobeNewswire

Humacyte Announces Presentation of First Eight Expanded Access Cases Using Human Acellular Vessel™ (HAV) for Treatment of Critical Limb Ischemia at 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society

06 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Humacyte Announces Presentation of First Preclinical Results of the HAV™ in Coronary Artery Bypass Grafting at Advanced Therapies Week Conference

04 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Humacyte Announces the Appointments of Three Surgical and Cardiovascular Opinion Leaders to Advisory Roles

31 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

Humacyte Announces Publication Highlighting the First Use of the Human Acellular Vessel (HAV™) as Arterial Bypass Conduit for Replacement of Infected Prosthetic Graft

15 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

Humacyte Presents Preclinical Results of Small-Diameter HAV™ for Use as a BTT Shunt in Pediatric Heart Disease at American Heart Association’s Scientific Sessions 2021

16 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

Humacyte Presents New 12-Month Data from HAVs™ Produced Using Commercial-Scale Manufacturing System

15 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Humacyte Reports Third Quarter 2021 Financial Results and Provides Business Highlights

12 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

Humacyte Leadership to Present at Credit Suisse 30th Annual Healthcare Conference

09 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

Humacyte Leadership to Present at Multiple Scientific Events in November

08 Nov 2021 06:30:00 By Nasdaq GlobeNewswire